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MaBACKGROUND Recent trials of ﬁsh oil for the prevention of atrial ﬁbrillation (AF) recurrence have provided mixed
results. Notable uncertainties in the existing evidence base include the roles of high-dose ﬁsh oil, inﬂammation, and
oxidative stress in patients with paroxysmal or persistent AF not receiving conventional antiarrhythmic (AA) therapy.
OBJECTIVES The aim of this study was to evaluate the inﬂuence of high-dose ﬁsh oil on AF recurrence, inﬂammation,
and oxidative stress parameters.
METHODS We performed a double-blind, randomized, placebo-controlled, parallel-arm study in 337 patients with
symptomatic paroxysmal or persistent AF within 6 months of enrollment. Patients were randomized to ﬁsh oil (4 g/day)
or placebo and followed, on average, for 271  129 days.
RESULTS The primary endpoint was time to ﬁrst symptomatic or asymptomatic AF recurrence lasting >30 s. Secondary
endpoints were high-sensitivity C-reactive protein (hs-CRP) andmyeloperoxidase (MPO). The primary endpoint occurred in
64.1% of patients in the ﬁsh oil arm and 63.2% of patients in the placebo arm (hazard ratio: 1.10; 95% conﬁdence interval:
0.84 to 1.45; p¼0.48). hs-CRP andMPOwerewithin normal limits at baseline anddecreased to a similar degree at 6months
(Dhs-CRP, 11% vs. 11%; DMPO, 5% vs. 9% for ﬁsh oil vs. placebo, respectively; p value for interaction ¼ NS).
CONCLUSIONS High-dose ﬁsh oil does not reduce AF recurrence in patients with a history of AF not receiving con-
ventional AA therapy. Furthermore, ﬁsh oil does not reduce inﬂammation or oxidative stress markers in this population,
which may explain its lack of efﬁcacy. (Multi-center Study to Evaluate the Effect of N-3 Fatty Acids [OMEGA-3] on
Arrhythmia Recurrence in Atrial Fibrillation [AFFORD]; NCT01235130) (J Am Coll Cardiol 2014;64:1441–8) © 2014 by the
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ABBR EV I A T I ON S
AND ACRONYMS
AA = antiarrhythmic
AAD = antiarrhythmic drug
AF = atrial ﬁbrillation
DHA = docosahexaenoic acid
EPA = eicosapentaenoic acid
hs-CRP = high-sensitivity
C-reactive protein
MPO = myeloperoxidase
PUFA = polyunsaturated
fatty acid
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possess antiarrhythmic (AA) properties and
provide protection from ventricular arrhyth-
mias and sudden death (3,4). As a conse-
quence, their potential utility for the
prevention and treatment of AF has been
suggested. Both higher consumption of fresh
ﬁsh and higher blood n-3 PUFA levels are
associated with a lower incidence of de
novo AF (5–7). However, randomized trials
of ﬁsh oil for the prevention of AF recurrence
have provided mixed results to date (8–12).
Importantly, these trials had several method-ological limitations and did not attempt to evaluate
potential underlying mechanisms.SEE PAGE 1449The AFFORD (Multi-center Study to Evaluate the
Effect of N-3 Fatty Acids [OMEGA-3] on Arrhythmia
Recurrence in Atrial Fibrillation) was designed to
assess the efﬁcacy of high-dose n-3 PUFAs for the
prevention of AF recurrence, inﬂammation, and
oxidative stress among patients with a documented
history of symptomatic, paroxysmal, or persistent AF
within 6 months of enrollment.
METHODS
STUDY DESIGN. The AFFORD was a Canadian,
multicenter, randomized, double-blind, placebo-
controlled, parallel-group trial that sought to test the
efﬁcacy of high-dose ﬁsh oil versus placebo on AF
recurrence, inﬂammation, and oxidative stress among
patients with a history of paroxysmal or persistent AF
who had a rhythm-control strategy planned. The
study was conducted at 23 sites across Canada. All
centers obtained approval from an institutional re-
view board, and all study participants provided writ-
ten informed consent. Patients were recruited from
March 2009 to March 2012, with follow-up ending on
December 15, 2012. Please see the Online Appendix for
a list of study investigators and committee members.
STUDY POPULATION. Eligible patients were those
18 years of age and older with a history of documented,
symptomatic paroxysmal or persistent AF lasting
$10 min within 6 months of enrollment, who had a
rhythm-control strategy planned by the treating physi-
cian. Major exclusion criteria were AF continuously pre-
sent for $3 months, the need for continued class I or III
AA therapy, New York Heart Association functional class
III-IV heart failure, left ventricular ejection fraction
<40%, known secondary cause of AF (e.g., hyperthy-
roidism, fever, anemia, postoperative AF), and the use of
n-3 PUFA supplements within 3 months of enrollment.STUDY INTERVENTION. Subjects were randomized to
2 1-g enteric-coated capsules of ﬁsh oil twice daily
(total dose 4 g/day) or matching placebo (Genuine
Health, Toronto, Ontario, Canada). Each 1-g ﬁsh oil
capsule contained 400 mg of eicosapentaenoic acid
(EPA) and 200 mg of docosahexaenoic acid (DHA).
Placebo capsules consisted of 1 g of safﬂower oil.
Safﬂower oil is free of n-3 PUFAs and has no pur-
ported AA effects. Given the pharmacokinetic proﬁle
of EPA þ DHA after long-term ingestion (13,14), a
3-week loading phase represented a balance between
adequate incorporation of n-3 PUFAs into biological
tissues permitting potential AA effects and achieving
a steady state for maximal efﬁcacy. Therefore, treat-
ment began at enrollment, with patients ﬁrst en-
tering a 3-week loading/blanking phase and then a
follow-up phase beginning on day 22. Patients not
in sinus rhythm on day 21 were required to undergo
cardioversion; failed cardioversion was considered
an AF recurrence. Patients were followed for 6 to
16 months. Patients who had an AF recurrence
before 6 months were followed until the 6-month
study visit, with class I or III AA therapy permitted
after the ﬁrst recurrence. Patients without AF re-
currence at 6 months were followed until the ﬁrst
AF recurrence or for 16 months.
Recurrence of AF was monitored by weekly trans-
telephonic monitor transmissions to detect poten-
tially asymptomatic episodes, whereas symptomatic
episodes were assessed by transtelephonic monitor
strips, 12-lead electrocardiography or any implanted
device. The omega-3 index, representing the eryth-
rocyte membrane content of EPA þ DHA as a percent
of total membrane fatty acids, was used as a measure
of adherence to study medication and performed at
baseline and at AF recurrence or the 6-month visit,
whichever occurred ﬁrst.
STUDY ENDPOINTS. The primary endpoint was time
to ﬁrst asymptomatic or symptomatic AF recurrence
lasting $30 s. Secondary endpoints, high-sensitivity
C-reactive protein (hs-CRP) and myeloperoxidase
(MPO) were measured at baseline and at 6-month
follow-up visit. Tertiary endpoints included bleeding
and cardiovascular-related death or hospitalization.
An independent events committee adjudicated AF
recurrences, bleeding, strokes, transient ischemic at-
tacks, and deaths.
SAMPLE SIZE CALCULATION AND STATISTICAL
ANALYSES. In our unpublished randomized pilot
study in 45 patients, we observed a 3-month AF
recurrence rate of 50% in the placebo group, 42% in
the low-dose (1.2 g/day EPA þ DHA), and 36% in the
high-dose (2.4 g/day EPA þ DHA) ﬁsh oil group (p for
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FIGURE 1 Pathophysiology of Atrial Fibrillation
Ca2+ ¼ calcium.
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1443trend ¼ NS). Furthermore, in the CTAF (Canadian
Trial of Atrial Fibrillation), we observed a 6-month AF
recurrence rate of w35% with sotalol or propafenone
(15). On the basis of these data, we estimated a total
sample size of 332 patients, assuming a 6-month AF
recurrence rate of 65% in the placebo group and 50%
in the ﬁsh oil group, an accrual period of 10 months, a
maximal follow-up of 16 months, a yearly loss of 10%,
90% power, and a 2-sided p value of 0.05.
A data safety monitoring committee was created to
oversee safety endpoints, including bleeding. No
interim efﬁcacy analysis was performed. The com-
mittee met 3 times during the course of the trial and
recommended that the trial proceed as planned.
Efﬁcacy analyses were performed in a pre-speciﬁed
manner on the modiﬁed intention-to-treat population
consisting of all patients completing the loading
phase and entering the follow-up period. Safety
endpoints were performed on the safety population,
which consisted of all participants who consumed at
least 1 dose of study medication. The primary analysis
consisted of an unadjusted comparison of time to ﬁrst
AF recurrence using the log-rank test. Kaplan-Meier
estimates were displayed graphically as survival
curves. Censoring occurred if the patient was lost to
follow-up, died, or reached the end of the follow-up
period without relapse. Secondary efﬁcacy analyses
were performed using analysis of covariance on log-
transformed data. Safety endpoints, including major
and minor bleeding and cardiovascular-related death
or hospitalization, were compared between groups
using chi-square analysis. All analyses were per-
formed using SAS version 9.1 (SAS Institute, Cary,
North Carolina). Results are expressed as numbers
and percent for categorical variables and mean  SD
for continuous variables, with the exception of hs-
CRP and MPO, which are expressed as mean, mini-
mum, and maximum. A p value <0.05 was considered
statistically signiﬁcant.
RESULTS
A total of 337 patients were randomized, of whom 297
(88%) completed the study (Figure 2). Subjects not
completing the study were distributed equally in both
groups and related primarily to withdrawal of consent
(30%) and nonserious adverse events (28%). Baseline
demographic, clinical, and cardiac characteristics and
medication were similar between treatment groups
(Table 1).
PRIMARY OUTCOME MEASURE. The overall rate of
AF recurrence was high (63.6%) but did not differ
between groups (Central Illustration, Table 2). Fur-
thermore, the number of days in follow-up, percentof asymptomatic episodes, and number of AF relapses
at 6 months were similar between groups. Results
were consistent across all subgroups, except for a
signiﬁcantly higher AF recurrence for ﬁsh oil users
with any ischemic heart disease (hazard ratio: 2.6;
95% conﬁdence interval: 1.1 to 6.1); however, the ab-
solute numbers were small, and the multiple testing
suggests that this association is likely spurious
(Figure 3).
SECONDARY OUTCOME MEASURES. MPO and hs-
CRP were similar between groups at baseline and
were within normal limits (Table 3). Values of both
markers decreased modestly over 6 months for all
patients, although no signiﬁcant treatment  time
interaction was noted.
TERTIARY SAFETY ENDPOINTS, ADVERSE EVENTS,
AND WITHDRAWALS. Although minor bleeding oc-
curred in 10 (7%) patients in the ﬁsh oil group and 14
(9%) in the placebo group (p ¼ 0.5), no major bleeding
occurred. One patient in the ﬁsh oil group experi-
enced a stroke during the loading phase; the patient
was withdrawn from the study, although the event
was deemed unrelated to the study drug. Two pa-
tients in the placebo group experienced transient
ischemic attacks. In both cases, study medication was
continued, and the patients fully recovered. One
death occurred in the placebo group; this was deemed
unrelated to study drugs. The composite endpoint
of cardiovascular-related death or hospitalization
occurred in 20 patients in the ﬁsh oil group (13%) and
11 (7%) in the placebo group (p ¼ 0.06; 95%
TABLE 1 Baseline Characteristics
Fish Oil
(n ¼ 153)
Placebo
(n ¼ 163)
Demographic and medical variables
Age, yrs 60  12 62  13
Female 48 (31) 57 (35)
BMI, kg/m2 29  5 29  6
Waist circumference, cm 99  12 97  13
Diabetes 10 (7) 16 (10)
Hypertension 69 (45) 68 (42)
Coronary disease 22 (14) 21 (13)
Valvular disease 1 (1) 3 (2)
Class I/II heart failure 5 (3) 3 (2)
Cardiac and echocardiography parameters
Sinus rhythm at baseline 139 (91) 150 (92)
12-lead ECG heart rate, beats/min 62  13 62  11
Left atrial dimension, cm 3.9  0.6 4.2  3.6
Left ventricular hypertrophy on echo 6/100 (6) 7/112 (6)
Left ventricular ejection fraction, % 61  7 61  7
AF history
Paroxysmal AF 103 (67) 107 (66)
Persistent AF 50 (33) 56 (34)
Time since ﬁrst AF diagnosis, yrs 2.5  4.4 1.9  3.4
Class I or III AAD use in 12 months
before enrollment
37 (24) 20 (12)
Concomitant medications
Beta-blockers 60 (39) 62 (38)
ACEI or ARB 68 (44) 59 (36)
Oral anticoagulant 105 (69) 91 (56)
Values are mean  SD or n (%).
AAD ¼ antiarrhythmic drug; ACEI ¼ angiotensin-converting enzyme inhibitor;
AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass
index; ECG ¼ electrocardiography.
337 Patients enrolled
172 Randomized to placebo 165 Randomized to fish oil
144 Completed study153 Completed study
19 Did not complete study





6 Adverse events
1 Lost to follow-up
7 Withdrew consent
1 Death prior to
entering follow-up
4 Others





21 Did not complete study
5 Adverse events
3 Protocol violations
6 Lost to follow-up
5 Withdrew consent
2 Others
163 Included in efficacy
analysis
(Modified ITT population)
153 Included in efficacy
analysis
(Modified ITT population)
FIGURE 2 Study Flow Chart
ITT ¼ intention-to-treat.
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related to hospitalizations for AF (10 vs. 7 patients in
the ﬁsh oil and placebo groups, respectively; p ¼ 0.4).
Study medication was generally well tolerated.
Only 17 patients (10 placebo, 7 ﬁsh oil) experienced an
adverse event leading to discontinuation of study
medication. Of these events, 11 (6 placebo, 5 ﬁsh oil)
were deemed related to study treatment, primarily
gastrointestinal side effects.
OMEGA-3 INDEX. As expected, the omega-3 index
was similar between groups at baseline and was
signiﬁcantly increased in the ﬁsh oil group relative to
the placebo group during follow-up (Figure 4). How-
ever, the index did not differ between patients with
and without AF recurrence at 6months, irrespective of
treatment group. Furthermore, the change in omega-3
index from baseline was also not associated with a
higher or lower risk of AF recurrence (data not shown).
DISCUSSION
Our study demonstrates that high-dose, long-chain
n-3 fatty acids do not reduce symptomatic or
asymptomatic AF recurrence or the number of re-
currences over a follow-up period of up to 16 monthsamong patients with paroxysmal or persistent AF
not receiving conventional AA therapy (Central
Illustration). Importantly, ﬁsh oil at the dose used
also had no impact on hs-CRP or MPO, suggesting that
although both inﬂammation and oxidative stress may
be implicated in the pathophysiology of AF, ﬁsh oil
had no effect on either mechanism, which may
explain its lack of efﬁcacy.
To date, randomized trials of ﬁsh oil for the pre-
vention of AF recurrence have provided mixed,
generally negative results (8–12). The AFFORD is
comparable to the 2 largest studies with respect to
sample size and methodology (8,9). In the ﬁrst
(8), ﬁsh oil had no effect relative to placebo on the
recurrence of symptomatic AF or ﬂutter after
24 weeks. Similarly, in the FORWARD (Randomized
Trial to Assess Efﬁcacy of PUFA for the Maintenance
of Sinus Rhythm in Persistent Atrial Fibrillation)
(9), ﬁsh oil did not reduce episodes of symptomatic
AF recurrence after 1 year compared with pla-
cebo. Importantly, all trials had $1 methodological
Days
0.2
0.0
0.8
0.4
0.6
1.0
0 50 100 150 200 250 300 350 400 450 500
Su
rv
iv
al
 P
ro
ba
bi
lit
y
1: OMEGA=3
2: Placebo  
Treatment group
Product-Limit Survival Estimates
with Number of Subjects at Risk
1
2
153 90 77 71 68 64 53 44 41 20 1
163 112 95 84 072 68 60 56 51 23
HR=1.10 (0.84 - 1.45) P=0.48
CENTRAL ILLUSTRATION Time to First Symptomatic or Asymptomatic
Atrial Fibrillation
AF ¼ atrial ﬁbrillation; HR ¼ hazard ratio.
TABLE 2 AF Outcomes
Fish Oil
(n ¼ 153)
Placebo
(n ¼ 163) p Value
AF outcomes
Recurrence 98 (64) 103 (63) 0.5
Total follow-up time, days 266  126 275  132 0.8
Asymptomatic episodes, % 26 36 0.2
Relapses 4 (0, 28) 2.6 (0, 38) 0.09
Time to ﬁrst AF recurrence,
days*
82  115 103  118 0.08
Values are n (%), mean  SD, or mean (minimum, maximum). *Only for patients
with a recurrence.
AF ¼ atrial ﬁbrillation.
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1445limitations including the following: 1) open-label
design and lack of placebo-control group (12); 2) a
potentially inadequate treatment dose (generally 1.0
to 1.7 g/dl EPAþDHA) (9–12); 3) the lack of an adequate
initial loading/blanking phase (6–9) given the phar-
macokinetic proﬁle of n-3 PUFAs after ingestion
(13,14); 4) the lack of consideration of asymptomatic
AF episodes, which represent a signiﬁcant proportion
of the total AF burden (8,9,12) and are associated
with a higher risk of stroke (16,17); 5) lesser capture
of recurrent AF episodes due to the method of
assessment used (generally 24-h Holter monitor or
12-lead electrocardiography) (8–10,12); 6) the lack
of measurement of blood n-3 fatty acids as a mea-
sure of treatment adherence and efﬁcacy (8–10,12);
and 7) signiﬁcant use of AADs, including amiodarone,
in patients with a higher baseline risk of AF
recurrence (9–12). Finally, little if any attempt was
undertaken to evaluate potential underlying mecha-
nisms (8–12).
Given the limitations of previous trials discussed in
the preceding text, the AFFORD has several notable
strengths. 1) The dose that we used (4 g/day) is
generally considered the highest dose of ﬁsh oil free
from gastrointestinal side effects; a higher dose
would have made blinding not feasible in the context
of a randomized, placebo-controlled trial. Again, we
chose this dose because of our pilot data, showing
potentially greater efﬁcacy for the prevention of AF
recurrence relative to the standard 1-g/day dose rec-
ommended for the secondary prevention of coronary
heart disease. Only the study by Kowey et al. (8) used
a comparable ﬁsh oil dose. 2) As noted previously, n-3
fatty acids must incorporate into cell membranes to
exert their effects; steady-state plasma levels are
achieved only after several weeks (13). Thus, a 3-week
loading phase was incorporated into our study before
AF recurrence was included in the primary outcome
measures. This was not done in most previous trials
(8–11). 3) We included both asymptomatic and
symptomatic AF recurrence in our primary endpoints.
4) All participants were provided with a trans-
telephonic monitor and required to transmit rhythm
strips at least weekly, enabling a more complete
capture of recurrent AF episodes relative to most
previous studies. 5) We assessed the omega-3 index
as a measure of adherence to study medication. This
further allowed us to demonstrate the lack of efﬁcacy
of ﬁsh oil for the endpoints of interest in our study.
6) Our data demonstrate that in patients at lower
risk of AF recurrence high-dose ﬁsh oil lacks efﬁcacy
in the absence of class I or III AA therapy. Two-
thirds of AFFORD participants had a diagnosis of
paroxysmal AF, and only 9 had received amiodaronetreatment in the year before study inclusion. Thus,
they represented ideal patients for demonstrating
the efﬁcacy or lack thereof of ﬁsh oil as a sole AA
agent for the prevention of AF recurrence. Finally,
knowing that inﬂammation and oxidative stress are
involved in the pathophysiology of AF, our study is
the ﬁrst to prospectively evaluate markers of both of
these mechanisms as potential targets for n-3 fatty
acids.
Omega-3 fatty acids are known to reduce systemic
inﬂammation and oxidative stress (18,19); both
mechanisms contribute to atrial remodeling and both
the initiation and recurrence of AF (20,21). In our
study, hs-CRP was not elevated at baseline (mean
Age ≤ 65 years
Age > 65 years
Male
Female
BMI ≤ 28 kg/m2
BMI > 28 kg/m2
Waist circ. ≤ 97 cm
Waist circ. > 97 cm
Diabetes - yes
Diabetes - no
Hypertension - yes
Hypertension - no
Coronary disease - yes
Coronary disease - no
Paroxysmal AF
Persistent AF
Duration* ≤ 4 months
Duration* > 4 months
AAD use in past year - yes
AAD use in past year - no
LA diameter ≤ 39 cm
LA diameter > 39 cm
0.125 0.475 0.825 1 2 3 4 5 6
Hazard Ratio and 95% CI
FIGURE 3 Occurrence of Primary Endpoint in
Pre-Speciﬁed Subgroups
*Time since ﬁrst diagnosis of AF. AAD ¼ antiarrhythmic drugs;
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CI ¼ conﬁdence
interval; circ. ¼ circumference; LA ¼ left atrial.
TABLE 3 Change in Inﬂammatory and Oxidative Stress Markers
From Baseline to 6 Months
Baseline
Mean (min, max) % Change p Value
p Value
Interaction
hs-CRP, mg/dl
Fish oil 2.11 (0.17, 9.62) 11 0.04 0.9
Placebo 1.98 (0.17, 9.87) 11 0.04
MPO, ng/ml
Fish oil 80 (18, 305) 5 0.05 0.3
Placebo 79 (25, 300) 9 0.0004
Values are mean (minimum, maximum) unless otherwise indicated.
hs-CRP ¼ high-sensitivity C-reactive protein; MPO ¼ myeloperoxidase.
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groups. Similarly, MPO was within normal limits at
baseline and decreased slightly in both groups
(Table 3). Our ﬁndings raise 2 potential hypotheses.
First, given the low values of both CRP and MPO in
our sample, these mechanisms may not have been
implicated in AF recurrence in AFFORD. Second, ﬁsh
oil at the given dose may have been insufﬁcient
to further reduce these markers in this low-risk
population.
Although previous studies showed an inverse
relationship between n-3 fatty acid blood content
and risk of de novo AF (6,7), ours is the ﬁrst study
to prospectively address the relationship between
the omega-3 index and AF recurrence. We observed
a doubling of the omega-3 index in patients in
the ﬁsh oil group (w8%), whereas it remainedunchanged in the placebo group (Figure 4). Previ-
ously, an omega-3 index $8% was noted to be
associated with optimal cardioprotection and a 90%
reduction in the risk of sudden cardiac death (22).
Although we achieved this level in the AFFORD, ﬁsh
oil did not provide protection against recurrent
atrial arrhythmias. The omega-3 index was similar
between those with and without an AF recurrence,
and the change in omega-3 index at follow-up was
also not associated with a higher or lower risk of AF
recurrence, irrespective of treatment group (data
not shown).
STUDY LIMITATIONS. Potential limitations of the
current study include the formulation of n-3 PUFA
supplements used. Fish oil capsules contained EPA
and DHA in a 2:1 ratio, whereas certain data suggest
that DHA may have greater AA properties than EPA
(6,21,23,24). However, this ratio was protective
against sudden arrhythmic death in the GISSI-
Prevenzione study (25). Second, participants were
not ﬁtted with implantable loop recorders that,
although costly and invasive, would have, in theory,
provided the optimal means for detection of AF
recurrence. As a more cost-effective alternative, pa-
tients had transtelephonic monitors, allowing them to
transmit rhythm strips at will. Again, previous trials of
ﬁsh oil for the prevention of AF recurrence generally
used 12-lead electrocardiography or 24-h Holter
monitors to detect recurrent episodes. Third, we did
not assess the potential impact of ﬁsh oil in combi-
nation with either AADs or following AF ablation.
However, as noted previously and in contrast to pre-
viously mentioned studies (9–12), the speciﬁc purpose
of the AFFORD was to evaluate the efﬁcacy of ﬁsh oil
as the sole AA agent in a group of low-risk patients.
Additionally, data on the efﬁcacy of ﬁsh oil after
AF ablation are very limited, with 1 small, nested
case-control study suggesting some beneﬁt (26).
Fourth, although we observed a trend toward a higher
98
7
6
5
4
3
2
1
0
Baseline 6 Months AF/No AF
Fish oil
Placebo
AF
No AF
*P<0.0001
FIGURE 4 Omega-3 Index at Baseline, 6 Months, and According to the Presence
or Absence of AF Recurrence.
AF ¼ atrial ﬁbrillation.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Although ﬁsh
oils exhibit certain anti-inﬂammatory and antioxidant properties,
these substances do not reduce inﬂammation or oxidative stress
in low-risk patients with atrial ﬁbrillation or prevent arrhythmia
recurrence.
TRANSLATIONAL OUTLOOK: Whether interventions such
as the Mediterranean diet reduce the risk of recurrent atrial
ﬁbrillation after cardioversion or ablation requires further
investigation in prospective studies.
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1447risk of cardiovascular death or hospitalization in the
ﬁsh oil group, we believe this association to be
spurious due to small numbers and multiple testing.
Again, most of these endpoints were hospitalizations
for AF recurrence. Furthermore, previous studies
in AF (8–12) and large studies in coronary heart dis-
ease (25,27) have not shown ﬁsh oil to be associated
with a higher risk of death, but suggest that it
may even be protective (25). Finally, we made no
effort to control for dietary sources of omega-3 fatty
acids and no dietary counseling was provided to par-
ticipants. Although certain macronutrients, including
omega-6 fatty acids, reﬁned sugars, and processed
meats, are known to be pro-inﬂammatory (28–30) and
therefore could potentially inﬂuence hs-CRP, given
the randomized nature of the study and sample size,
a signiﬁcant diet  treatment group interaction is
unlikely.
CONCLUSIONS
Among low-risk patients with paroxysmal or persis-
tent AF not receiving conventional AA therapy, ﬁsh
oil used at a higher dose than in most previous
studies does not reduce symptomatic or asymptom-
atic AF recurrence. Furthermore, ﬁsh oil at the
dose used did not lower systemic markers of inﬂam-
mation and oxidative stress. The lack of a beneﬁcial
effect of ﬁsh oil on AF recurrence in the AFFORD may
be at least partially due to its lack of effect on
these pathophysiological processes, which have been
implicated in AF development and progression.
We believe that our results provide conclusive evi-
dence that ﬁsh oil has no role in the rhythm-control
management of patients with paroxysmal or persis-
tent AF.
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